XENOTRANSPLANTATION FOR BRAIN REPAIR
- 1 July 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (2) , 190-196
- https://doi.org/10.1097/00007890-200107270-00004
Abstract
Background. Transplantation of embryonic neural tissue is a potential treatment for Parkinson’s disease. Because human donor material is in short supply, porcine xenografts are considered a useful alternative. Current immunosuppressive therapies fail, however, to protect intracerebral neural xenografts from host CD4 T lymphocytes. To reduce the immunogenicity of porcine donor tissue, we attempted to remove microglial cells with antibodies against the α-galactosyl epitope (Galα1,3Galβ1,4GlcNAc-R), or anti-Gal, and complement, and studied whether this pretreatment can reduce direct and indirect T-cell responses to the tissue. Methods. Brain tissue from 27-day-old pig embryos was dissociated and treated with human anti-Gal and rabbit complement. The microglial content was analyzed by flow cytometry. [3H]thymidine incorporation in cocultures of the brain cells and purified human CD4 T cells was used to determine direct T-cell responses. Indirect T-cell responses were studied by grafting pretreated and control-pretreated (no anti-Gal) nigral tissue into the lesioned striatum of immunocompetent rats with 6-hydroxydopamine-induced hemiparkinsonism. Amphetamine-induced circling behavior was used to measure graft function. Results. Anti-Gal and complement reduced the microglial content to 11–24% of control and abolished the ability of the brain cells to induce human CD4 T-cell proliferation. Pretreated nigral tissue reduced hemiparkinsonism by more than 50% in five of eight rats at some point during the 10-week follow-up. Rats receiving control-pretreated nigral tissue did not display this degree of improvement. Conclusions. Pretreatment with anti-Gal and complement can reduce the immunogenicity of porcine neural tissue, and might, therefore, be a valuable alternative or supplement to immunosuppression in neural xenotransplantation.Keywords
This publication has 38 references indexed in Scilit:
- Expression of Major Histocompatibility Complex Antigens and Induction of Human T-Lymphocyte Proliferation by Astrocytes and Macrophages from Porcine Fetal BrainExperimental Neurology, 1999
- Human Natural Antibodies Cytotoxic to Pig Embryonic Brain Cells Recognize Novel Non-Galα1,3Gal-Based XenoantigensExperimental Neurology, 1999
- Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's diseaseMovement Disorders, 1998
- XENOGENEIC TRANSPLANTATIONAnnual Review of Immunology, 1998
- Major Histocompatibility Complex (MHC) Class I Gene Expression in Single Neurons of the Central Nervous System: Differential Regulation by Interferon (IFN)-γ and Tumor Necrosis Factor (TNF)-αThe Journal of Experimental Medicine, 1997
- Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brainNature Biotechnology, 1996
- Antigen processing and presentation in transplantationCurrent Opinion in Immunology, 1996
- Fetal nigral transplantation as a therapy for Parkinson's diseaseTrends in Neurosciences, 1996
- Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humansImmunology Today, 1993
- Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.The Journal of Experimental Medicine, 1992